Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Individualised cancer vaccine - Immunovative Therapies

Next Previous
X
Search
Drug Profile

Individualised cancer vaccine - Immunovative Therapies

Alternative Names: AlloVax; CRCL-AlloVax

Latest Information Update: 27 Sep 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunovative Therapies
  • Developer Immunovative Inc; Immunovative Therapies
  • Class Antineoplastics; Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Head and neck cancer
  • No development reported Haematological malignancies; Liver cancer

Most Recent Events

  • 27 Sep 2021 No development reported - Phase-II for Liver cancer (Late-stage disease, Second-line therapy or greater) in Thailand (Intradermal) (Immunovative therapies pipeline, September 2021)
  • 27 Jan 2020 Immunovative Therapies completes a phase II trial in head and neck cancer (Metastatic disease, Second line therapy or greater) in Thailand (Intradermal) (NCT01998542)
  • 22 Jan 2020 Immunovative Therapies withdraws a phase II trial for Head and neck cancer (Late-stage disease, Metastatic disease) in Thailand, prior to enrollment (NCT02624999)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top